Triumvira Submits Investigational New Drug (IND) Application to the FDA and Clinical Trial Application (CTA) to Health Canada to Evaluate TAC01-CD19, a T Cell Antigen Coupler Therapy, in Ph 1/2 TACTIC-19 Trial


AUSTIN, Texas & HAMILTON, Ontario–(BUSINESS WIRE)–Triumvira submits IND to FDA and CTA to Health Canada to initiate a Phase 1/2, first-in-human trial of its T cell therapy product to fight cancer.

- Advertisement -